Skip to main content
Full access
Letters
Published Online: 1 January 2014

Challenges in Diagnosing and Adequately Treating Malignant Catatonia and Its Fatal Consequences

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Catatonia may often present with puzzling symptoms and etiologies that can delay adequate and timely treatment, increasing the risk of mortality.1 When accompanied with hyperthermia and autonomic instability, it is called malignant catatonia (MC).1,2 When preceded by antipsychotic use, catatonia is usually termed and treated as neuroleptic malignant syndrome (NMS), which is regarded as a variant of MC.1,3 The case below inspired us to highlight the challenges in diagnosing and adequately treating MC and its fatal consequences.
An 82-year-old man with Bipolar-I disorder (BD) consulted in the Neurology-ICU for failure to respond to an adequate trial of bromocriptine3,4 (7.5 mg/day for 20 days) administered as a hospital practice, depending on the provisional diagnosis of olanzapine-induced NMS. Reportedly, he was taken to ER and then transferred to the Neurology-ICU with acute-onset insomnia, fever (38.5°C), excessive sweating, hypertension (140/90 mmHg), tachycardia (105 bpm), diffuse rigidity, elevated serum-CPK, and delirium state marked by fluctuating consciousness and lying naked on the floor with extreme resistance to being moved. Head injury, metabolic disorders, seizures, infections, and intoxication were all excluded with comprehensive history and labs. His BD was in remission for 6 months with valproate sodium 1,000 mg/day and olanzapine 5 mg/day. However, he had discontinued both medications 1 week before admission. Clinical history and bedside examination that revealed diffuse rigidity and immobility associated with disturbances in thought, mood, and vigilance suggested catatonia, and accompanying hyperthermia and autonomic instability suggested MC.1,2 The retarded/stuporous variant of catatonia was predominant throughout the entire hospital stay, although he sometimes displayed several signs of the excited form, as reported.2 We reformulated the phenomena by considering the following diagnostic elements: First, discontinuation of olanzapine 1 week before admission would significantly reduce the possibility of NMS,1 which should have been considered at intake. Second, he failed to respond to an adequate trial of bromocriptine,3,4 a specific treatment for NMS. Therefore, on the 21st day of MC, we initiated lorazepam 5 mg/day and increased it to 12.5 within a few days. We preferred lorazepam because of its ease of administration, wide margin of safety,3 fast response,2,3 the absence of cardiovascular challenge even at high doses, unlike ECT,2,3 the fact that there is no need for anesthesia, and that it is less stigmatizing than ECT. We maintained an adequate trial of lorazepam1,3,5 for 28 days, with little improvement in catatonia. We decided to administer ECT for its efficacy in relieving MC where benzodiazepines have failed (a response rate of 89% to ECT, 40% to benzodiazepines),2 but we could not. The patient died of aspiration pneumonia developed during stuporous exhaustion.
We took several lessons from this case. Hierarchy of treatment selection in catatonia should consider all variants and etiologies. Although benzodiazepines and ECT can treat both malignant and non-malignant catatonia, bromocriptine is peculiar to NMS, that is, neuroleptic-induced MC.3 To satisfy all needs with one deed, ECT can be the first-choice treatment in life-threatening catatonic states due to restriction of oral intake,5 having breached the malignancy threshold,1,2 and long duration of catatonia that predicts poor response to benzodiazepines,5 and that it can quickly relieve catatonia, accompanying delirium, and the underlying psychiatric disorder.4

References

1.
Detweiler MB, Mehra A, Rowell T, et al.: Delirious mania and malignant catatonia: a report of three cases and review. Psychiatr Q 2009; 80:23–40
2.
Daniels J: Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371–380
3.
Fink M, Taylor MA: Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1182–1183; author reply 1184–1185
4.
Fink M: Delirious mania. Bipolar Disord 1999; 1:54–60
5.
Narayanaswamy JC, Tibrewal P, Zutshi A, et al.: Clinical predictors of response to treatment in catatonia. Gen Hosp Psychiatry 2012; 34:312–316

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E52
PubMed: 24515714

History

Published online: 1 January 2014
Published in print: Winter 2014

Authors

Details

Erol Ozan, M.D.
Celal Bayar University School of Medicine Department of Psychiatry, Türkiye
Esat Fahri Aydin, M.D.
Atatürk University School of Medicine Department of Psychiatry, Türkiye

Notes

Correspondence: Dr. Ozan; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share